Core Insights - Patria Investments has agreed to acquire RBR Gestão de Recursos Ltda, enhancing its position as the leading manager of listed REITs in Brazil and increasing its scale in credit and multi-asset strategies [1][3] - The acquisition will add approximately US$ 1.3 billion of Fee Earning Assets under Management (FEAUM), bringing Patria's total Real Estate FEAUM to US$ 8.5 billion pro-forma as of Q3 2025, reflecting a Compound Annual Growth Rate (CAGR) of over 65% since its IPO in early 2021 [2] Company Overview - Patria is a global alternative asset manager with a strong presence in Latin America and Europe, managing over US$ 51 billion in assets [4] - The company specializes in resilient and growth sectors, leveraging local expertise to identify compelling investment opportunities [4] Transaction Details - The acquisition is expected to close in Q1 2026 and is anticipated to be accretive to both Fee Related Earnings (FRE) and Distributable Earnings (DE) in the first year [3] - Post-acquisition, Patria will manage 12 funds, predominantly focused on Credit and Multi-Asset strategies, solidifying its leadership in the Brazilian REIT market [1][3]

JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonproprietary Names (I ...

CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it has been granted lab licenses to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor ...

Core Insights - Abeona Therapeutics Inc. has activated The University of Texas Medical Branch (UTMB) as a Qualified Treatment Center (QTC) for ZEVASKYN, a gene-modified cellular therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [1][3] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being the first autologous cell-based gene therapy for RDEB [10] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [10] Product Information - ZEVASKYN (prademagene zamikeracel) is the first FDA-approved autologous gene therapy for RDEB, designed to treat chronic wounds by incorporating the COL7A1 gene into a patient's skin cells [5][6] - The therapy has shown clinically meaningful results in wound healing and pain reduction with a single surgical application [5] Treatment Center Activation - The activation of UTMB as a QTC significantly enhances patient access to ZEVASKYN across Texas and the Gulf Coast region, reflecting UTMB's commitment to innovative care [3] - UTMB is recognized for its expertise in complex skin diseases and wound care, making it an ideal partner for delivering ZEVASKYN [2][3] Patient Support Services - Abeona offers a comprehensive patient support program called Abeona Assist, which provides personalized assistance, including help with insurance benefits, financial options, and logistical support for patients [3]

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS -- -- Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist RM-718 in patients with PWS -- -- Company to hold conference call on Thursday, December 11 at 8:00 a.m. -- BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rhythm P ...

Core Insights - Roivant is at a transformational moment with opportunities for three major product launches, each representing a pipeline-in-a-product opportunity with blockbuster potential [2] - The company is hosting an Investor Day to discuss pipeline updates and long-term value creation strategies [1][9] Program-Specific Highlights and Updates - Brepocitinib is expected to have its NDA filing for dermatomyositis in early 2026, with a commercial launch anticipated in early 2027 [6][7] - The Phase 3 trial for brepocitinib in non-infectious uveitis is fully enrolled, with topline data expected in the second half of 2026 [6][7] - A proof-of-concept trial for brepocitinib in cutaneous sarcoidosis is also fully enrolled, with topline data expected in the first half of 2026 [6][7] - IMVT-1402's potentially registrational trial in difficult-to-treat rheumatoid arthritis is expected to provide topline data in 2026 [6][7] - The ongoing Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease is on track, with topline data expected in the second half of 2026 [5][8] Financial and Strategic Developments - Roivant's financing efforts alongside key institutional investors generated approximately $550 million for Immunovant, extending its cash runway to the launch of IMVT-1402 in Graves' disease [6][7] - The company is well-positioned to generate shareholder value through its late-stage pipeline and long-term strategy [2][6]

Core Insights - Caliber has staked 75,000 LINK tokens with a leading Chainlink node operator, marking its first direct involvement in the Chainlink Network's infrastructure [1][2][3] - The staking is part of Caliber's Digital Asset Treasury (DAT) strategy, aimed at providing public equity investors with transparent exposure to digital finance infrastructure [3][4] - Caliber expects to earn a token-denominated yield from its staked LINK while retaining possession and control of the tokens [2][3] Company Strategy - The staking initiative is a significant milestone in Caliber's DAT strategy, which focuses on actively supporting Chainlink's growth rather than passive holding of LINK [3][4] - By partnering with node operators, Caliber aims to participate in the economic value generated from the transformation of traditional finance to on-chain systems [5] - The company has a legacy of identifying misunderstood opportunities and aims to secure the core routing layer for modernizing global finance [5] Market Context - As of the announcement, the cumulative transaction value enabled by Chainlink's services reached $27 trillion, indicating substantial market activity [5] - Caliber's initiative positions it as an early participant in the evolving landscape of digital finance, with expectations of increased institutional support for node operators as the network matures [5][6] - The move reflects a broader trend of integrating traditional finance with blockchain technology, which is seen as a transformative shift in the industry [4][5]

DALLAS, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Beneficient (Nasdaq: BENF), a technology-enabled platform providing liquidity and related trust and custody services to holders of alternative assets, today announced a 1-for-8 reverse stock split (the “Reverse Stock Split”) of its Class A common stock, par value $0.001 per share (the “Class A Common Stock”), and its Class B common stock, par value $0.001 per share (“Class B Common Stock” and together with the Class A Common Stock, the “Common Stock”). The Reverse S ...

Engages Michael Pound to Provide Investor Relations ServicesVANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Domestic Metals Corp. (the “Company” or “Domestic”) - (TSXV: DMCU; OTCQB: DMCUF; FSE: 03E) announces the appointment of Gordon Neal as Chief Executive Officer of the Company. Mr. Neal has had a notable and successful career in the mining and resource sectors. He started as one of the founding members of MAG Silver Corp. before moving on to serve as the VP Corporate Development for Silv ...

Core Viewpoint - The Brink's Company has announced a new share repurchase program, reflecting confidence in its financial performance and future cash flow generation [2]. Group 1: Share Repurchase Program - The new share repurchase program is authorized for $750 million, representing more than 15% of the company's current market capitalization [2]. - This new authorization is in addition to a previous $500 million program that is set to expire on December 31, 2025 [2]. - The new program is expected to expire on December 31, 2027 [2]. Group 2: Financial Performance and Strategy - Brink's has a track record of consistent performance and anticipates an increase in free cash flow as it continues to execute its ATM managed services and digital retail solutions growth strategy [2]. - Since 2022, the company has retired over seven million shares and returned over $725 million in capital through dividends and share repurchases [2]. Group 3: Company Overview - The Brink's Company is a leading global provider of cash and valuables management, digital retail solutions, and ATM managed services, serving customers in over 100 countries [3]. - Its customer base includes financial institutions, retailers, government agencies, mints, jewelers, and other commercial operations [3].